Programs such as the 3 Wishes Project not only equip healthcare professionals with the tools to support critically ill patients at the end of life (EOL), but they also promote healthcare worker well-being by instilling a deeper sense of purpose in their work, authors reported in the results of their DNP project published in the June 2024 issue of the Clinical Journal of Oncology Nursing.

Median prostate-specific antigen (PSA) levels are lower in transgender women receiving estrogen than comparable cisgender men without a prostate cancer diagnosis, researchers reported in study findings published in JAMA, possibly because of the gender-affirming therapy’s castrating effects. The finding raises questions about the utility of PSA testing for transgender women with intact prostates.

Tarlatamab-dlle (Imdelltra™) was granted accelerated approval in May 2024 for the treatment of extensive-stage small cell lung cancer with progression on or after a platinum chemotherapy regimen.

President Biden and First Lady Jill Biden were in New Orleans on Tuesday to tout the Biden Cancer Moonshot initiative, which aims to boost funding research and treatment to prevent cancer deaths and help those living with the disease. Earlier in the day, the White House announced up to $150 million in awards to eight research teams across the country to develop technologies that will allow surgeons to provide more successful tumor-removal surgeries for people facing cancer.

In August 2024, the U.S. Food and Drug Administration (FDA) announced that ICU Medical issued an update recall to the use instructions for its Plum 360, Plum A+ and Plum A+3 infusion systems because of a manufacturing defect that can substantially diminish the life of the batteries. ICU Medical’s latest notice expands the affected products from a March 2023 notice to include all replacement batteries manufactured by CSB.

After experiencing challenges with a limited supply of private hospital rooms and high demands of patients awaiting room assignments, AtlantiCare Regional Medical Center, a community teaching hospital, assembled an interprofessional team of clinical partners united to create a solution. 

On August 19, 2024, the U.S. Food and Drug Administration (FDA) approved lazertinib (Lazcluze^™) in combination with amivantamab-vmjw (Rybrevant^®) for first-line treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution variants, as detected by an FDA-approved test.

Among the taxanes currently approved for breast cancer treatment, docetaxel is the preferred agent for Black patients with breast cancer, researchers concluded in study findings presented at the 2024 American Society of Clinical Oncology Annual Meeting. In a study that only enrolled Black patients with breast cancer, the researchers found that docetaxel was associated with the lowest risk for taxane-induced peripheral neuropathy, a dose-limiting adverse event that typically occurs more frequently in Black individuals.

In May 2023, the U.S. Food and Drug Administration (FDA) announced it had granted accelerated approval for the first CD20 bispecific antibody drug, epcoritamab-bysp (Epkinly^™) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In June 2024, the FDA expanded the indication with accelerated approval for the treatment of relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Five ONS members have been inducted into the American Academy of Nursing’s (AAN’s) 2024 Class of Fellows, which this year recognizes 200 exemplary nurses who have engaged in significant activity and leadership in the profession.